Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market

Executive Summary

AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.

Advertisement

Related Content

Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
GSK's Nucala Shows Promise In A Rare Systemic Vasculitis
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Teva Under Pressure As NICE Calls For More Reslizumab Analyses
AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch
AstraZeneca Looks To Insmed To Advance AZD7986 In Bronchiectasis
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register